Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib + PD-1 Inhibitor in Advanced Solid Tumors With 11q13 Amplification
NCT07417501Phase 2Recruiting
- Sponsor
- Tongji Hospital
- Start
- May 2026
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenvatinib in solid tumor, sponsored by Tongji Hospital. Started May 2026; status: recruiting.
02
Drugs
lenvatinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07417501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07417501.